LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

Home・Akciju saraksts・Simulations Plus Inc

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

16.99 2.04

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

16.98

Max

17.43

Galvenie mērījumi
By Trading Economics
Ienākumi	-70M -67M
Pārdošana	-2.1M 20M
P/E Sektora vidējais	48.528 106.172
Dividenžu ienesīgums	0.48
Peļņas marža	-330.585
Darbinieki	243
EBITDA	327K 5.3M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	-5.88% downside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	0.48% 2.31%
Nākamie ieņēmumi	2025. g. 1. dec.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-9.6M 342M
Iepriekšējā atvēršanas cena	14.95
Iepriekšējā slēgšanas cena	16.99

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 23. nov. 22:23 UTC

Iegādes, apvienošanās, pārņemšana

BHP Abandons Bid for Anglo American Following New Talks

2025. g. 23. nov. 22:16 UTC

Iegādes, apvienošanās, pārņemšana

Macquarie Proposes $7.5 Billion Takeover of Logistics Operator Qube

2025. g. 23. nov. 22:01 UTC

Iegādes, apvienošanās, pārņemšana

Macquarie Proposes $7.5B Takeover of Logistics Operator Qube

2025. g. 23. nov. 19:00 UTC

Peļņas

Dell, HP Inc., Alibaba, Zoom, Deere, and More Stocks to Watch This Week -- Barrons.com

2025. g. 23. nov. 00:50 UTC

Peļņas

Wall Street Goes on a Wild Ride: 'No One Was Expecting This' -- WSJ

2025. g. 22. nov. 10:30 UTC

Peļņas

How Google Finally Leapfrogged Rivals With New Gemini Rollout -- WSJ

2025. g. 22. nov. 10:30 UTC

Iegādes, apvienošanās, pārņemšana

Investors Clamor for a Peek Behind the Private Markets Curtain -- WSJ

2025. g. 22. nov. 09:20 UTC

Tirgus saruna

Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 21. nov. 22:42 UTC

Tirgus saruna

Fitch Raises Cyprus's Outlook to Positive From Stable -- Market Talk

2025. g. 21. nov. 21:50 UTC

Tirgus saruna

Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 21. nov. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 21. nov. 21:47 UTC

Tirgus saruna

Mexico's 3Q GDP Prompts Growth Downgrades -- Market Talk

2025. g. 21. nov. 21:43 UTC

Tirgus saruna

U.S. Crude Production Defies Low Prices, Rig Count -- Market Talk

2025. g. 21. nov. 20:18 UTC

Tirgus saruna

Oil Futures Fall on U.S. Push for Russia-Ukraine Peace -- Market Talk

2025. g. 21. nov. 20:14 UTC

Tirgus saruna

U.S. Natural Gas Gains As Traders Focus on Weather -- Market Talk

2025. g. 21. nov. 19:48 UTC

Tirgus saruna

Precious Metals Fall for the Week -- Market Talk

2025. g. 21. nov. 19:44 UTC

Peļņas

Deere Earnings, Inflation Data, Black Friday: What to Watch in the Next Week -- WSJ

2025. g. 21. nov. 19:37 UTC

Tirgus saruna

Dollar Stalls as Stocks and Bonds Rise -- Market Talk

2025. g. 21. nov. 19:27 UTC

Tirgus saruna

Peļņas

Global Equities Roundup: Market Talk

2025. g. 21. nov. 19:27 UTC

Tirgus saruna

Peļņas

Intuit Seen With Underappreciated Credit Karma Momentum -- Market Talk

2025. g. 21. nov. 19:20 UTC

Tirgus saruna

European Natural Gas Premium Versus U.S. Shrinks -- Market Talk

2025. g. 21. nov. 18:44 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Palo Alto-Chronosphere Synergies Questioned Despite M&A Record -- Market Talk

2025. g. 21. nov. 18:37 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By 2 to 419 -- Market Talk

2025. g. 21. nov. 18:34 UTC

Tirgus saruna

Peļņas

Intuit Seen Outperforming on Conservative Guidance -- Market Talk

2025. g. 21. nov. 18:28 UTC

Peļņas

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

2025. g. 21. nov. 18:03 UTC

Tirgus saruna

Mexico's Inflation Seen Up Slightly in Early November -- Market Talk

2025. g. 21. nov. 17:24 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 21. nov. 17:24 UTC

Tirgus saruna

Intuit Seen on Path to Increase Growth -- Market Talk

2025. g. 21. nov. 17:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 21. nov. 17:05 UTC

Tirgus saruna

Lowe's Getting Boost From Busy Small to Medium Pro Customer -- Market Talk

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

-5.88% uz leju

Prognoze 12 mēnešiem

Vidējais 16 USD -5.88%

Augstākais 16 USD

Zemākais 16 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.